Summary:
This is a Prospective, Randomized, Vehicle‐controlled, Double‐blind, Multi-center, 3-arm study assessing the safety, tolerability, and efficacy of B244 delivered as an intranasal spray for preventive treatment in subjects with episodic migraine.
Qualified Participants Must:
• Between the ages of 18-65
•
Experience 4-14 migraine days per month and 3-14 migraine attacks per month
•
At least 1 year history of migraine with or without aura that began before the age of 50 years old with a diagnosis of migraine with or without aura
Qualified Participants May Receive:
May be compensated for time and travel.